Cargando…

A 12‐week DBPC dose‐finding study with sublingual monomeric allergoid tablets in house dust mite‐allergic patients

BACKGROUND: In sublingual immunotherapy, optimal doses are a key factor for therapeutic outcomes. The aim of this study with tablets containing carbamylated monomeric house dust mite allergoids was to determine the most effective and safe dose. METHODS: In this double‐blind, placebo‐controlled dose‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hüser, C., Dieterich, P., Singh, J., Shah‐Hosseini, K., Allekotte, S., Lehmacher, W., Compalati, E., Mösges, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217067/ https://www.ncbi.nlm.nih.gov/pubmed/27068870 http://dx.doi.org/10.1111/all.12913

Ejemplares similares

Safety of injective immunotherapy with monomeric carbamylated allergoid given to pediatric patients with allergic rhinitis with/without asthma due to house dust mite
por: Compalati, Enrico, et al.
Publicado: (2015)

The relative clinical impact of sublingual immunotherapy with carbamylated monomeric allergoids on allergic respiratory symptoms
por: Compalati, Enrico, et al.
Publicado: (2015)

Peripheral effector memory regulatory T cells are incremented and functionally enhanced in successful mite monomeric allergoid sublingual immunotherapy
por: Petrarca, Claudia, et al.
Publicado: (2020)

Worldwide surveys on anaphylaxis to sublingual immunotherapy with house dust mite tablets are urgently needed
por: Mösges, Ralph, et al.
Publicado: (2021)

House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis
por: Okamoto, Y., et al.
Publicado: (2016)

Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy
por: Aarestrup, Matheus Fonseca, et al.
Publicado: (2021)

157 The Post-Treatment Efficacy of House Dust Mite Sublingual Allergen Immunotherapy Tablets in Adults With Allergic Rhinitis
por: Bergmann, Karl-Christian, et al.
Publicado: (2012)

Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?
por: Ellis, Anne K., et al.
Publicado: (2019)

Outcome of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitive to House Dust Mites
por: Kim, Seon-Tae
Publicado: (2015)

Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population
por: Okamoto, Yoshitaka, et al.
Publicado: (2018)

Efficacy and safety of house dust mite sublingual immunotherapy tablets in allergic rhinitis: A systematic review and meta-analysis
por: Kulalert, Prapasri, et al.
Publicado: (2022)

11 Efficacy and Tolerability of HDM Injective Immunotherapy With Monomeric Allergoid
por: Compalati, Enrico, et al.
Publicado: (2012)

O17 - Assessment of efficacy and safety of sublingual tablets of house dust mite allergen extract in children and adolescents with allergic rhinitis
por: Halken, Susanne, et al.
Publicado: (2014)

Early Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mites
por: Chang, Hyun, et al.
Publicado: (2009)

Poster 1000: Efficacy and safety of specific sublingual immunotherapy with carbamylated allergoid tablets of ragweed pollen: a dose-ranging study
por: Compalati, Enrico, et al.
Publicado: (2014)

Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite
por: Barberi, Salvatore, et al.
Publicado: (2015)

Real-Life Effectiveness of Subcutaneous Immune Therapy with Carbamylated Monomeric Allergoids on Mite, Grass, and Pellitory Respiratory Allergy: A Retrospective Study
por: Di Gioacchino, Mario, et al.
Publicado: (2022)

Acute systemic reactions to sublingual immunotherapy for house dust mite
por: Janssens, Nicky S., et al.
Publicado: (2020)

New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ(®) tablets
por: Vitiello, Gianfranco, et al.
Publicado: (2020)

Variation in allergen content in sublingual allergen immunotherapy with house dust mites
por: Moreno Benítez, F., et al.
Publicado: (2015)

Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust Mites
por: Kim, Shin Hye, et al.
Publicado: (2015)

Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
por: Trebuchon, Florence, et al.
Publicado: (2014)

Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients
por: Chen, Huan, et al.
Publicado: (2022)

First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy
por: Nieto, Antonio, et al.
Publicado: (2022)

Efficacy of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis: A Meta-Analysis of Randomized Controlled Trials
por: Feng, Bohai, et al.
Publicado: (2017)

Circulating MIF Associated With Disease Severity and Clinical Response of Sublingual Immunotherapy in House Dust Mite–Induced Allergic Rhinitis
por: Xie, Shaobing, et al.
Publicado: (2021)

Shrimp sensitization in house dust mite allergic patients
por: Ukleja-Sokołowska, Natalia, et al.
Publicado: (2020)

A meta‐analysis on allergen‐specific immunotherapy using MCT(®) (MicroCrystalline Tyrosine)‐adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis
por: Becker, Sven, et al.
Publicado: (2021)

Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis
por: Jordakieva, Galateja, et al.
Publicado: (2017)

Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis
por: Proctor, Thomas, et al.
Publicado: (2020)

In Vitro Evaluation of Allergen Potencies of Commercial House Dust Mite Sublingual Immunotherapy Reagents
por: Park, Kyung Hee, et al.
Publicado: (2015)

Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis
por: Liao, Wei, et al.
Publicado: (2015)

Efficacy and Safety of Sublingual Immunotherapy in Elderly Rhinitis Patients Sensitized to House Dust Mites
por: Kim, Ji Hye, et al.
Publicado: (2018)

Effectiveness of sublingual immunotherapy with house dust mite drops in asthmatic children at different ages
por: Ai, Tao, et al.
Publicado: (2023)

Precision Medicine in House Dust Mite-Driven Allergic Asthma
por: Eguiluz-Gracia, Ibon, et al.
Publicado: (2020)

Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children
por: Lim, Jae Hyun, et al.
Publicado: (2017)

Efficacy of dual sublingual immunotherapy with Japanese cedar pollen and house dust mite allergens in patients with allergic rhinitis sensitized to multiple allergens
por: Fujii, Tatsuya, et al.
Publicado: (2022)

Erratum: In Vitro Evaluation of Allergen Potencies of Commercial House Dust Mite Sublingual Immunotherapy Reagents
por: Park, Kyung Hee, et al.
Publicado: (2017)

Cost-effectiveness of SQ(®) HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany
por: Green, William, et al.
Publicado: (2017)

Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy
por: Kim, Nacksung, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ae5s3d0mhnu3jcjmfeklsl857t